Our Progress

By leveraging the company’s innovative development platform, MapLight has already brought two novel therapeutics into the clinic, with more on the horizon. Focused on solutions that serve populations currently struggling with either no treatment options or limited options with significant safety liabilities, MapLight’s initial therapeutics are aimed at safely targeting key symptoms of Autism Spectrum DisorderDyskinesia in Parkinson’s Disease, and Schizophrenia.
Learn more about our ASD clinical study » 1 of 4 Learn more about our Schizophrenia studies » 2 of 4 Learn more about our Parkinson’s Disease studies » 3 of 4 Learn more about our Parkinson’s Disease studies » 4 of 4

MapLight's focus on indications with high unmet medical need

Autism Spectrum Disorder

Dyskinesia in Parkinson’s Disease

Schizophrenia